Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

1. BACKGROUND: Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study was to identify predictive biomarkers for bevac...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Mol Oncol
Главные авторы: Urup, Thomas, Michaelsen, Signe Regner, Olsen, Lars Rønn, Toft, Anders, Christensen, Ib Jarle, Grunnet, Kirsten, Winther, Ole, Broholm, Helle, Kosteljanetz, Michael, Issazadeh-Navikas, Shohreh, Poulsen, Hans Skovgaard, Lassen, Ulrik
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2016
Предметы:
Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5423207/
https://ncbi.nlm.nih.gov/pubmed/27262894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2016.05.005
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы